Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ranjana Tavorath"'
Autor:
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim
Publikováno v:
Haematologica, Vol 102, Iss 12 (2017)
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinos
Externí odkaz:
https://doaj.org/article/fbd61fce20ad4a2095ca685859c745c8
Autor:
Andrew Eugene Hendifar, Ramon Salazar, Ranjana Tavorath, Nicholas S. Reed, O Kong, Enrique Grande, Tim Meyer, Ana Custodio, Rosine Guimbaud, Catherine Lombard-Bohas, Jaume Capdevila, Rocio Garcia-Carbonero, Annemiek M E Walenkamp, Heinz-Josef Klümpen, Sergio Ricci, Sufiya Safina, Steven K. Libutti, James C. Yao, Herve Salomon
Publikováno v:
Oncologist, 23(7), 766-e90. AlphaMed Press
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist, 23(7), 766-e90. ALPHAMED PRESS
The oncologist, vol 23, iss 7
oncologist, 23(7):e90. AlphaMed Press
The Oncologist
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist, 23(7), 766-e90. ALPHAMED PRESS
The oncologist, vol 23, iss 7
oncologist, 23(7):e90. AlphaMed Press
The Oncologist
Lessons Learned Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. The hypothesis of dual targeting of the phosphatidylinositol 3-kinase and ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08405e14763dc0ca2d0c8412ef9d9fbb
https://research.vumc.nl/en/publications/76e9f9bd-d8c4-4754-a699-02272811bb5e
https://research.vumc.nl/en/publications/76e9f9bd-d8c4-4754-a699-02272811bb5e
Autor:
Christina Coughlin, Nathalie Fretault, Samit Hirawat, Bharani Bharani-Dharan, Emmanuelle di Tomaso, Patrick Urban, Cristian Massacesi, Ranjana Tavorath, C. Germa, Cornelia Quadt
Publikováno v:
The Journal of OncoPathology. 3:27-39
Autor:
Gilles Salles, John F. Gerecitano, Eva González Barca, Robert G. Bociek, Chaitali Babanrao Pisal, Ranjana Tavorath, Mehmet Turgut, Giovanni Martinelli, Anas Younes, Won Seog Kim, Dolores Caballero Barrigon, O Kong
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Haematologica
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Haematologica
Martinelli, Giovanni/0000-0002-1025-4210; BARCA, EVA GONZALEZ/0000-0002-1323-1508 WOS: 000416867100031 PubMed: 28971900 Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605610cde688667bff21f6c119a26cea
http://hdl.handle.net/2445/124228
http://hdl.handle.net/2445/124228
Autor:
Emmanuelle di Tomaso, Bharani Dharan, C. Germa, Lucia Trandafir, Cornelia Quadt, Samit Hirawat, Patrick Urban, Cristian Massacesi, Ranjana Tavorath, Nathalie Fretault, Paola Aimone
Publikováno v:
OncoTargets and therapy
The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may ther
Autor:
Anas Younes, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, Dolores Caballero Barrigon, Eva Gonzalez Barca, Mehmet Turgut, John F. Gerecitano, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim
Publikováno v:
Blood. 126:1493-1493
Background: Patients (pts) with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including DLBCL, MCL, and FL, have poor outcomes and few therapy options. Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin
Autor:
Eva González Barca, Nabanita Mukherjee, Gilles Salles, R. Gregory Bociek, Anas Younes, Giovanni Martinelli, Fabian Herbst, Ranjana Tavorath, Won Seog Kim, L. S. Williams, Dolores Caballero
Publikováno v:
Blood. 124:1718-1718
Background: Patients (pts) with relapsed or refractory (R/R) non-Hodgkin9s lymphoma (NHL), including DLBCL, MCL, and FL, have poor outcomes and few therapy options. Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin
Autor:
Ranjana Tavorath, Paul J. Hesketh
Publikováno v:
Drugs. 52(5)
Chemotherapy-induced emesis has a major adverse impact on patients undergoing therapy for various malignancies, and this has led to considerable research in this field. Most investigative efforts have concentrated on the acute phase of emesis that oc